- Home
- INBX
INBX
Inhibrx Inc.
as 11-21-2025 3:32pm EST
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 430.2M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 458.6K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.80 - $86.64 | Next Earning Date: | 11-14-2025 |
| Revenue: | $1,400,000 | Revenue Growth: | -19.26% |
| Revenue Growth (this year): | 563% | Revenue Growth (next year): | 230.77% |
Stock Insider Trading Activity of Inhibrx Inc. (INBX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | INBX | 10% Owner | Oct 7 '25 | Sell | $32.25 | 350,000 | $11,287,500.00 | 1,267,823 |
Latest Inhibrx Inc. News
INBX Breaking Stock News: Dive into INBX Ticker-Specific Updates for Smart Investing
PR Newswire
10 days ago
Inhibrx Reports Third Quarter 2025 Financial Results
Zacks Small Cap Research
14 days ago
LGND: Target Up On Improved Growth Outlook
PR Newswire
20 days ago
Inhibrx Announces Participation in Upcoming Scientific Conferences
Clinical Trials Arena
a month ago
Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory
PR Newswire
a month ago
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
PR Newswire
a month ago
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Simply Wall St.
a month ago
Owning 45% shares,institutional owners seem interested in Inhibrx Biosciences, Inc. (NASDAQ:INBX),
Investor's Business Daily
4 months ago
Liquidia Stock Gets Relative Strength Rating Lift
Compare INBX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INBX Inhibrx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.